Comparative Pharmacology
Head-to-head clinical analysis: DEXTENZA versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTENZA versus EOHILIA.
DEXTENZA vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid with glucocorticoid activity that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune cell migration and activation.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Insert 0.4 mg intracanalicularly (into the lacrimal punctum) as a single dose; releases dexamethasone over 30 days.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
The terminal elimination half-life of dexamethasone from plasma after systemic absorption is approximately 3-4 hours. However, Dextenza provides sustained local delivery to the ocular surface; the insert releases dexamethasone over 30 days, with therapeutic levels maintained throughout.
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Dextenza (dexamethasone ophthalmic insert) is administered intracanalicularly; systemic absorption is minimal. Following release into the tear film, the drug is primarily eliminated via nasolacrimal drainage and subsequent gastrointestinal absorption with hepatic metabolism. Renal excretion accounts for <5% of the dose as unchanged drug; biliary/fecal elimination is negligible.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category C
Category C
Corticosteroid
Corticosteroid